Solid Biosciences granted Andelyn Biosciences a non‑exclusive worldwide license to use Solid’s next‑generation capsid AAV‑SLB101, intended to enhance skeletal muscle and cardiac tropism while reducing liver biodistribution. Solid cited robust preclinical and early clinical transduction in its INSPIRE DMD trial and said the license expands access for CDMO partners and early gene therapy programs. The license plugs into a broader gene therapy ecosystem push to diversify capsid options and manufacturing partnerships; Andelyn will offer AAV‑SLB101 via its modular AAV Curator® process. Solid noted more than 30 prior agreements for AAV‑SLB101 and framed the deal as enabling broader clinical access to vectors with differentiated tropism profiles. Separately, the field continues to reckon with clinical precedent: the FDA‑approved microdystrophin gene therapy Elevidys is reshaping expectations for DMD endpoints, safety monitoring, and postapproval evidence generation. Sponsors planning AAV programs must align capsid choice, biodistribution, and manufacturing with evolving regulatory expectations.